World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
56853
World Ranking
8123
National Ranking
796

Overview

Peter Hillmen is affiliated with St James's University Hospital in the United Kingdom and has contributed extensively to the field of medicine, with a focus on hematology and related disorders. Their scholarly work spans several specialized subfields including genetics, pathology and forensic medicine, immunology, hematology, and pulmonary and respiratory medicine.

The scientist's research topics prominently include chronic lymphocytic leukemia, lymphoma diagnosis and treatment, the complement system in diseases, immunodeficiency and autoimmune disorders, chronic myeloid leukemia treatments, blood groups and transfusion, and advanced breast cancer therapies.

Peter Hillmen has published significant articles in a variety of academic journals. Notable recent papers include:

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, 2021, Journal of Clinical Oncology
  • Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2020, Annals of Oncology
  • Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, 2022, New England Journal of Medicine
  • Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, 2021, New England Journal of Medicine
  • Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial, 2022, The Lancet Oncology

The venues where Peter Hillmen frequently publishes include Blood, Clinical Lymphoma Myeloma & Leukemia, British Journal of Haematology, Journal of Clinical Oncology, and Haematologica. These journals reflect their focus on hematological and oncological research.

Their collaborative network consists of several frequent co-authors, including:

  • Paolo Ghia
  • Jennifer R. Brown
  • Tadeusz Robak
  • Wojciech Jurczak
  • John C. Byrd

Hillmen's contributions have helped advance knowledge in chronic lymphocytic leukemia research, with many focused studies on therapeutic approaches and clinical outcomes in hematologic malignancies. Their work on the complement system has also addressed its role in various diseases, including paroxysmal nocturnal hemoglobinuria.

Best Publications

  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

    Russell P. Rother;Leonard Bell;Peter Hillmen;Mark T. Gladwin

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Neal S. Young;Jörg Schubert;Robert A. Brodsky

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • Natural history of paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;S.M. Lewis;Monica Bessler;Lucio Luzzatto

  • Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

    Charles Parker;Mitsuhiro Omine;Stephen Richards;Jun-Ichi Nishimura

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    John F. Seymour;Thomas J. Kipps;Barbara Eichhorst;Peter Hillmen

  • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

    D Catovsky;S Richards;E Matutes;D Oscier

  • Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Claire Hall;Judith C W Marsh;Modupe Elebute

  • Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    William G. Wierda;Thomas J. Kipps;Jiří Mayer;Stephan Stilgenbauer

  • Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

    Andy C Rawstron;Fiona L Bennett;Sheila J M O'Connor;Marwan Kwok

  • Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

    Robert A. Brodsky;Neal S. Young;Elisabetta Antonioli;Antonio M. Risitano

  • Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

    Peter Hillmen;Aleksander B. Skotnicki;Tadeusz Robak;Branimir Jaksic

  • Guidelines for the diagnosis and management of adult aplastic anaemia.

    Sally B Killick;Nick Bown;Jamie Cavenagh;Inderjeet Dokal

  • Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Petra Muus;Ulrich Dührsen;Antonio M. Risitano

Frequent Co-Authors

Andy C. Rawstron
Andy C. Rawstron Leeds Teaching Hospitals NHS Trust
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Susan O'Brien
Susan O'Brien University of California, Irvine
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Steven Coutre
Steven Coutre Stanford University
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Anna Schuh
Anna Schuh University of Oxford
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Jennifer R. Brown
Jennifer R. Brown Harvard University
Tadeusz Robak
Tadeusz Robak Medical University of Lodz

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online health-related degrees is a flexible way to enter or advance in the medical field beyond traditional pathways. For those interested in pharmacy, understanding online pharmacy school cost can help you budget for further studies and make informed choices about your education investment.

If your interests align with healthcare administration and data, consider pursuing an online mhi (Master of Health Information Management) program. This option prepares you for critical roles in managing patient records and healthcare information systems.

For those seeking a quicker entry into the medical workforce, billing and coding classes online offer focused training for essential administrative positions, with courses ranging from a few months to a year.

Aspiring advanced clinicians may look into nurse practitioner programs, which can offer the convenience of online study while preparing for high-demand, patient-facing roles.

Best Scientists Citing Peter Hillmen

Trending Scientists